Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Drug</td><td class="align_center">Agent description</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Ipilimumab</td><td class="align_center">The inhibition of CTLA-4</td></tr><tr><td class="align_left">Pembrolizumab (previously known as MK-3475 and lambrolizumab)</td><td class="align_center">The inhibition of PD-1</td></tr><tr><td class="align_left">Pidilizumab</td><td class="align_center">The inhibition of PD-1</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

The blockade of immune checkpoints in prostate cancer.

Journal of Immunology Research

tab3

Table 3

Table 3: Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review 